2089 - Coadministration of Intranasal M2SR (M2-deficient Single Replication) Investigational Influenza Vaccine with Fluzone High Dose Induces Superior Immune Responses to Fluzone High Dose Alone in 65-85 Year Old Adults

Rapid Fire Presenter(s)

• JE

  Joseph Eiden, MD, PhD (he/him/his)

  Senior Clinical Consultant
  FluGen, Inc.
  Madison, WI, United States

Co-Author(s)

• CF

  Carlos Fierro, M.D.

  Investigator
  Johnson County Clin-Trials
  Lenexa, Kansas, United States
• AW

  Alexander White, M.D.

  Progressive Medical Research
  Port Orange, Florida, United States
• MD

  Matthew Davis, M.D.

  Medical Director
  Rochester Clinical Research
  Rochester, New York, United States
• MR

  Margaret Rhee, M.D.

  Velocity Clinical Research
  Cleveland, Ohio, United States
• MT

  Mark Turner, M.D.

  Velocity Clinical Research
  Boise, Idaho, United States
• BM

  Bryan Murray, M.D.

  Boyds Consultants
  Crewe, England, United Kingdom
• RH

  Renee Herber, B.S.

  VP, R&D Operations
  FluGen, Inc.
  Madison, Wisconsin, United States
• RA

  Roger Aitchison, ScM

  Principal
  North Rim Consulting
  Longmont, Colorado, United States
• DM

  David Marshall, B.S.

  FluGen, Inc.
  Madison, Wisconsin, United States
• MM

  Michael Moser, Ph.D.

  FluGen, Inc.
  Madison, Wisconsin, United States
• PB

  Pamuk Bilsel, Ph.D.

  CSO
  FluGen, Inc.
  Madison, Wisconsin, United States